Mode
Text Size
Log in / Sign up
N/A Completed N=14 Basic Science

Vascular Dysfunction During Physical Inactivity

Aging · Vascular Endothelium · Skeletal Muscle
Source: ClinicalTrials.gov NCT04872998 ↗
Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Feb 2024
Primary outcomePrimary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation

Summary

Prolonged periods of reduced activity are associated with decreased vascular function and muscle atrophy. Physical inactivity due to a sedentary lifestyle or acute hospitalization is also associated with impaired recovery, hospital readmission, and increased mortality. Older adults are a particularly vulnerable population as functional (vascular and skeletal muscle mitochondrial dysfunction) and structural deficits (loss in muscle mass leading to a reduction in strength) are a consequence of the aging process. The combination of inactivity and aging poses an added health threat to these individuals by accelerating the negative impact on vascular and skeletal muscle function and dysfunction. The underlying factors leading to vascular and skeletal muscle dysfunction are unknown, but have been linked to increases in oxidative stress. Additionally, there is a lack of understanding of how vascular function is impacted by inactivity in humans and how these changes are related to skeletal muscle function. It is the goal of this study to investigate the mechanisms that contribute to disuse muscle atrophy and vascular dysfunction in order to diminish their negative impact, and preserve vascular and skeletal muscle function.

Outcome Measures

OutcomeResultp-value
PRIMARY
Brachial Artery Vascular Function
5.1; 3.1; 4.4
SECONDARY
Popliteal Artery Vascular Function
4.5; 2.4; 3.6
SECONDARY
Leg Microvascular Function
385; 311; 412

Eligibility Criteria

Inclusion Criteria

  • Individuals who have recently undergone surgery or injury requiring inactivity

Exclusion Criteria

  • Cardiac abnormalities considered exclusionary by the study physician (congestive heart failure, coronary artery disease, right-to-left shunt)
  • Uncontrolled endocrine or metabolic disease
  • Glomerular filtration rate 180 or a diastolic blood pressure > 110
  • Implanted electronic devices such as pacemakers, infusion pumps, stimulators
  • Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma
  • Currently on a weight-loss diet or body mass index > 35 kg/m^2
  • Inability to abstain from smoking for duration of study
  • History of > 20 pack per year smoking
  • Positive for human immunodeficiency virus, hepatitis B or hepatitis C
  • Recent anabolic or corticosteroids use (within 3 months)
  • Subjects with hemoglobin or hematocrit lower than accepted lab values
  • Agitation/aggression disorder
  • History of stroke with motor disability
  • Recent history (< 12 months) of gastrointestinal bleed
  • Depression diagnosis
  • Alcohol or drug abuse
  • Liver disease (AST/ALT 2 times above the normal limit, hyperbilirubinemia)
  • Respiratory disease (acute upper respiratory infection, history of chronic lung disease with resting oxygen saturation < 97% on room air)
  • Pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04872998). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search